US 11642384
Compositions and methods for the treatment of Netherton Syndrome
granted A61KA61K35/763A61K38/1748
Quick answer
US patent 11642384 (Compositions and methods for the treatment of Netherton Syndrome) held by Krystal Biotech, Inc. expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Krystal Biotech, Inc.
- Grant date
- Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K35/763, A61K38/1748, A61K38/39, A61K38/57